Deep-Sea Marine Metabolites as Promising Anti-Tubercular Agents: CADD-Guided Targeting of the F420-Dependent Oxidoreductase
Marine Drugs · 2026
DOI: 10.3390/md24020058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2026. Verfasst von Ria Desai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Oxidoreductases, Aquatic Organisms. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation (HOTBIO), Department for Environment Food and Rural Affairs (DEEPEND), European Union’s Horizon 2020 research and innovation programme for the HOTBIO project under the Marie Skłodowska-Curie Grant Agreement.
Abstract (Originalsprache)
Tuberculosis, caused by Mycobacterium tuberculosis (M. tb), remains a leading global threat, escalated now by the rise of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains. In search of a novel anti-tubercular agent with a distinct mechanism of action, this study explores deep-sea marine metabolites as potential inhibitors of the F420-dependent oxidoreductase Rv1155, a redox enzyme essential for M. tb survival. A total of 2773 marine-derived compounds curated from the CMNPD, Reaxys, and MarinLit databases were screened using an integrated CADD workflow combining molecular docking, in-silico ADMET profiling, and molecular dynamics (MD) simulations. Docking identified 68 metabolites with strong affinity (−10.98 to −15.95 kcal/mol) for the Rv1155 binding pocket, and from which three compounds, Upenamide (CMNPD_22964), Aspyronol (Compound_1749), and Fiscpropionate F (Compound_1796), were shortlisted as hit candidates. Among these, Upenamide displayed the strongest binding (ΔG = −28.56 kcal/mol) with stable RMSD and hydrogen bond persistence during 100 ns MD simulation, while Aspyronol demonstrated a promising ADMET profile comparable to the native cofactor F4202. MM-GBSA analysis further confirmed the strong binding strength (ΔG _bind = −24.77 to −34.07 kcal/mol) for all three hit candidates. These findings confirm the strong and stable interaction of selected deep-sea marine metabolites with Rv1155. This validated screening pipeline established here provides a cost-effective framework for future experimental validation and expansion to additional F420-related drug targets in M. tb.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, UK.
- Honorary Research Fellow, Rowett Institute, University of Aberdeen, Aberdeen AB25 2ZD, UK.
- Department of Pharmaceutics and Pharmaceutical Biotechnology, Faculty of Pharmacy, Mutah University, Karak 61710, Jordan.
ORCID-Profile: Ria Desai, Amane A Alaroud, Gagan Preet, Rishi Vachaspathy Astakala, Rainer Ebel, Marcel Jaspars
Förderung
- UK Research and Innovation (HOTBIO)
- Department for Environment Food and Rural Affairs (DEEPEND)
- European Union’s Horizon 2020 research and innovation programme for the HOTBIO project under the Marie Skłodowska-Curie Grant Agreement
Zitieren
APA
Desai, R., Alaroud, A. A., Preet, G., Astakala, R. V., Ebel, R., & Jaspars, M. (2026). Deep-Sea Marine Metabolites as Promising Anti-Tubercular Agents: CADD-Guided Targeting of the F420-Dependent Oxidoreductase. Marine Drugs. https://doi.org/10.3390/md24020058
Vancouver
Desai R, Alaroud AA, Preet G, Astakala RV, Ebel R, Jaspars M. Deep-Sea Marine Metabolites as Promising Anti-Tubercular Agents: CADD-Guided Targeting of the F420-Dependent Oxidoreductase. Marine Drugs. 2026. doi:10.3390/md24020058
BibTeX
@article{Desai2026,
author = {Desai, Ria and Alaroud, Amane A and Preet, Gagan and Astakala, Rishi Vachaspathy and Ebel, Rainer and Jaspars, Marcel},
title = {Deep-Sea Marine Metabolites as Promising Anti-Tubercular Agents: CADD-Guided Targeting of the F420-Dependent Oxidoreductase},
journal = {Marine Drugs},
year = {2026},
doi = {10.3390/md24020058}
}
EUVIMED